Correlation between Protoporphyrin IX Fluorescence Intensity, Photobleaching, Pain and Clinical Outcome of Actinic Keratosis Treated by Photodynamic Therapy

Background: Photodynamic therapy (PDT) with Metvix® is a good therapeutic option to treat actinic keratosis, but it presents drawbacks (pain, lesion recurrences, heterogeneous outcome), emphasizing the possible need to individualize treatment. Objective: We assessed whether PDT clinical outcome and pain during treatment were correlated with protoporphyrin IX fluorescence intensity and photobleaching. Methods: 25 patients were treated by Metvix PDT. The outcome was evaluated after 1.3 (±0.4), 7.6 (±1.8), 13.2 (±1.2) and 33.6 (±3.0) months. After administration of Metvix, red light (632 ± 10 nm) was delivered with a light-emitting diode panel device. The outcome was assessed on a cosmetoclinical scale. Results: All patients who showed a fluorescence level before PDT treatment above a certain threshold had a complete recovery at 33.6 (±3.0) months. Conclusion: Our approach could be used to individualize PDT treatment based on the pretreatment fluorescence level, and to predict its long-term outcome.

[1]  L. Guillou,et al.  Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. , 2003, The Journal of urology.

[2]  P. Monnier,et al.  Optimizing light dosimetry in photodynamic therapy of early stage carcinomas of the esophagus using fluorescence spectroscopy , 1996, Lasers in surgery and medicine.

[3]  Murad Alam,et al.  The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. , 2004, Clinics in dermatology.

[4]  M S Patterson,et al.  Singlet oxygen luminescence as an in vivo photodynamic therapy dose metric: validation in normal mouse skin with topical amino-levulinic acid , 2005, British Journal of Cancer.

[5]  Michael S Patterson,et al.  Photobleaching kinetics, photoproduct formation, and dose estimation during ALA induced PpIX PDT of MLL cells under well oxygenated and hypoxic conditions , 2006, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[6]  Claire D. Johnson.  Measuring Pain. Visual Analog Scale Versus Numeric Pain Scale: What is the Difference? , 2005, Journal of chiropractic medicine.

[7]  E. Maytin,et al.  Pain associated with aminolevulinic acid-photodynamic therapy of skin disease. , 2009, Journal of the American Academy of Dermatology.

[8]  D. Salomon,et al.  Comparison of ALA- and ALA hexyl-ester-induced PpIX depth distribution in human skin carcinoma. , 2008, Journal of photochemistry and photobiology. B, Biology.

[9]  Cynthia C. Morton,et al.  Intraindividual, right–left comparison of topical methyl aminolaevulinate‐photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study , 2006, The British journal of dermatology.

[10]  A. Lucky,et al.  Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. , 2003, Journal of the American Academy of Dermatology.

[11]  J. Moan,et al.  Kinetics of Photobleaching of Protoporphyrin IX in the Skin of Nude Mice Exposed to Different Fluence Rates of Red Light , 1998, Photochemistry and photobiology.

[12]  G. Langley,et al.  The visual analogue scale: Its use in pain measurement , 2004, Rheumatology International.

[13]  Tayyaba Hasan,et al.  In-vivo singlet oxygen dosimetry of clinical 5-aminolevulinic acid photodynamic therapy. , 2008, Journal of biomedical optics.

[14]  D. Salomon,et al.  Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study. , 2002, Journal of the American Academy of Dermatology.

[15]  N. Conrad,et al.  Incipient intraepidermal cutaneous squamous cell carcinoma: a proposal for reclassifying and grading solar (actinic) keratoses. , 1999, Seminars in cutaneous medicine and surgery.

[16]  C. Berking,et al.  Topical Methyl Aminolevulinate Photodynamic Therapy Using Red Light‐Emitting Diode Light for Multiple Actinic Keratoses: A Randomized Study , 2009, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[17]  Petras Juzenas,et al.  Effectiveness of different light sources for 5-aminolevulinic acid photodynamic therapy , 2004, Lasers in Medical Science.

[18]  R. M. Szeimiesa,et al.  Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study. , 2002 .

[19]  D. Salomon,et al.  Correlations between photoactivable porphyrins' fluorescence, erythema and the pain induced by PDT on normal skin using ALA-derivatives. , 2013, Photodiagnosis and photodynamic therapy.

[20]  M. Corazza,et al.  Photodynamic therapy: parameters predictive of pain , 2010, The British journal of dermatology.

[21]  Stanley B. Brown,et al.  Fluorescence Photobleaching of ALA‐induced Protoporphyrin IX during Photodynamic Therapy of Normal Hairless Mouse Skin: The Effect of Light Dose and Irradiance and the Resulting Biological Effect , 1998, Photochemistry and photobiology.

[22]  Sean McLoone,et al.  Aminolaevulinic acid diffusion characteristics in ‘in vitro’ normal human skin and actinic keratosis: implications for topical photodynamic therapy , 2008, Photodermatology, photoimmunology & photomedicine.

[23]  J. Mones,et al.  Solar (actinic) keratosis is squamous cell carcinoma , 2006, The British journal of dermatology.

[24]  S. Campbell,et al.  Protoporphyrin IX photobleaching during the light irradiation phase of standard dermatological methyl-aminolevulinate photodynamic therapy. , 2010, Photodiagnosis and photodynamic therapy.

[25]  K. Svanberg,et al.  A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. , 2005, Acta dermato-venereologica.

[26]  H. Wulf,et al.  Cold water and pauses in illumination reduces pain during photodynamic therapy: a randomized clinical study. , 2009, Acta dermato-venereologica.

[27]  E. Jeffes,et al.  Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light. , 2001, Journal of the American Academy of Dermatology.

[28]  Q. Peng,et al.  5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. , 1997, Cancer.

[29]  P. Box.  Correlation between macroscopic fluorescence and protoporphyrin IX content in psoriasis and actinic keratosis following application of aminolevulinic acid , 2006 .

[30]  P. van Erp,et al.  Pretreatment to Enhance Protoporphyrin IX Accumulation in Photodynamic Therapy , 2008, Dermatology.

[31]  T. Gambichler,et al.  In vivo data of epidermal thickness evaluated by optical coherence tomography: effects of age, gender, skin type, and anatomic site. , 2006, Journal of dermatological science.

[32]  C. MacAulay,et al.  Fluorescence spectroscopy and imaging for skin cancer detection and evaluation , 2000 .

[33]  Even Angell-Petersen,et al.  Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate. , 2006, The Journal of investigative dermatology.

[34]  Thomas H Foster,et al.  Irradiance-Dependent Photobleaching and Pain in δ-Aminolevulinic Acid-Photodynamic Therapy of Superficial Basal Cell Carcinomas , 2008, Clinical Cancer Research.

[35]  J. Moan,et al.  A spectroscopic study of the photobleaching of protoporphyrin IX in solution , 2003, Lasers in Medical Science.

[36]  H. Lui,et al.  Methyl aminolevulinate-PDT for actinic keratoses and superficial nonmelanoma skin cancers. , 2009, Skin therapy letter.

[37]  Carin Sandberg,et al.  Important factors for pain during photodynamic therapy for actinic keratosis. , 2006, Acta dermato-venereologica.

[38]  Wiley Interscience,et al.  Protoporphyrin IX fluorescence photobleaching is a useful tool to predict the response of rat ovarian cancer following hexaminolevulinate photodynamic therapy , 2008, Lasers in surgery and medicine.

[39]  A. Enk,et al.  Factors influencing pain intensity during topical photodynamic therapy of complete cosmetic units for actinic keratoses. , 2010, Journal of the American Academy of Dermatology.

[40]  Tayyaba Hasan,et al.  Photobleaching‐based Dosimetry Predicts Deposited Dose in ALA‐PpIX PDT of Rodent Esophagus , 2007, Photochemistry and photobiology.

[41]  M. Ericson,et al.  Review of photodynamic therapy in actinic keratosis and basal cell carcinoma , 2008, Therapeutics and clinical risk management.

[42]  Marloes M. Kleinpenning,et al.  Fluorescence diagnosis in actinic keratosis and squamous cell carcinoma , 2010, Photodermatology, photoimmunology & photomedicine.

[43]  J Moan,et al.  5‐Aminolevulinic acid‐based photodynamic therapy , 1997, Cancer.

[44]  Alison Curnow,et al.  The relationship between protoporphyrin IX photobleaching during real‐time dermatological methyl‐aminolevulinate photodynamic therapy (MAL‐PDT) and subsequent clinical outcome , 2010, Lasers in surgery and medicine.

[45]  L. Lilge,et al.  Implicit and explicit dosimetry in photodynamic therapy: a New paradigm , 1997, Lasers in Medical Science.

[46]  L. Themstrup,et al.  Cryosurgery Treatment of Actinic Keratoses Monitored by Optical Coherence Tomography: A Pilot Study , 2012, Dermatology.

[47]  O Larkö,et al.  Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome , 2004, The British journal of dermatology.

[48]  C. Cockerell,et al.  New histopathological classification of actinic keratosis (incipient intraepidermal squamous cell carcinoma). , 2005, Journal of drugs in dermatology : JDD.

[49]  H. Moseley.  Light distribution and calibration of commercial PDT LED arrays , 2005, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[50]  M. Ericson,et al.  Pain caused by photodynamic therapy of skin cancer , 2002, Clinical and experimental dermatology.

[51]  J. Lang.  Pain during photodynamic therapy is associated with protoporphyrin IX fluorescence and fluence rate , 2009 .

[52]  C. Morton.  Methyl aminolevulinate (Metvix®) photodynamic therapy - practical pearls , 2003, The Journal of dermatological treatment.

[53]  C. Hadjur,et al.  Pharmacokinetics of Tetra (m‐hydroxyphenyl)chlorin in Human Plasma and Individualized Light Dosimetry in Photodynamic Therapy , 1998, Photochemistry and photobiology.

[54]  P. V. D. van de Kerkhof,et al.  Correlation between macroscopic fluorescence and protoporphyrin IX content in psoriasis and actinic keratosis following application of aminolevulinic acid. , 2005, The Journal of investigative dermatology.

[55]  R. Geronemus,et al.  Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: A randomized, double-blind, placebo-controlled study. , 2008, Journal of the American Academy of Dermatology.

[56]  Hans Christian Wulf,et al.  Pain associated with photodynamic therapy using 5-aminolevulinic acid or 5-aminolevulinic acid methylester on tape-stripped normal skin. , 2003, Archives of dermatology.

[57]  H. Kerl,et al.  Guidelines for the management of actinic keratoses. , 2006, European journal of dermatology : EJD.

[58]  Jarod C Finlay,et al.  The role of photodynamic therapy (PDT) physics. , 2008, Medical physics.

[59]  P. C. van de Kerkhof,et al.  The clinical efficacy of topical methyl-aminolevulinate photodynamic therapy in moderate to severe actinic keratoses of the face and scalp , 2010, The Journal of dermatological treatment.

[60]  M G Nichols,et al.  The Mechanism of Photofrin Photobleaching and Its Consequences for Photodynamic Dosimetry , 1997, Photochemistry and photobiology.

[61]  A. Pickert.  Treatment of actinic keratoses. , 2012, Cutis.